Vinorelbine and cisplatin in patients with advanced non-small cell lung cancer with interstitial pneumonia

N Watanabe, S Niho, K Kirita, S Umemura… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: The aim of the present study was to investigate the efficacy and tolerability of
vinorelbine and cisplatin for the treatment of patients with advanced (stage IIIB, IV or …

Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial …

K Okuda, T Hirose, Y Oki, Y Murata… - Anticancer …, 2012 - ar.iiarjournals.org
Background: Acute chemotherapy-associated exacerbation of interstitial lung disease (ILD)
can occur in patients with non-small cell lung cancer (NSCLC). The safety and efficacy of …

Weekly paclitaxel in combination with carboplatin for advanced non-small-cell lung cancer complicated by idiopathic interstitial pneumonias: a single-arm phase II …

A Fukuizumi, Y Minegishi, M Omori, K Atsumi… - International journal of …, 2019 - Springer
Abstract Background Idiopathic interstitial pneumonias (IIPs) are associated with increased
risk of lung cancer. In Japan, acute exaberation of IIPs induced by anticancer treatment is a …

Safety and efficacy of gemcitabine or pemetrexed in combination with a platinum in patients with non-small-cell lung cancer and prior interstitial lung disease

MK Choi, JY Hong, W Chang, M Kim, S Kim… - Cancer chemotherapy …, 2014 - Springer
Purpose The incidence of lung cancer in patients with interstitial lung disease (ILD) is higher
than in the general population; however, the clinical benefit of chemotherapy and the …

The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced non-small cell lung cancer with idiopathic interstitial pneumonias

Y Minegishi, J Sudoh, H Kuribayasi, H Mizutani… - Lung cancer, 2011 - Elsevier
BACKGROUND: Idiopathic interstitial pneumonias (IIPs) are one of the most common
complications in patients with lung cancer. In lung cancer patients with IIP, the most serious …

[HTML][HTML] Chemotherapy for non-small cell lung cancer complicated by idiopathic interstitial pneumonia

T Kinoshita, K Azuma, T Sasada… - Oncology …, 2012 - spandidos-publications.com
Idiopathic interstitial pneumonia (IIP) is considered to be one of the risk factors for lung
cancer (LC). However, therapeutic options for patients with LC complicated by IIP are not …

The safety and efficacy of treatment with nab-paclitaxel and carboplatin for patients with advanced squamous non-small cell lung cancer concurrent with idiopathic …

T Fujita, T Hiroishi, K Shikano, A Yanagisawa… - Internal …, 2018 - jstage.jst.go.jp
Objective Although lung squamous cell carcinoma (SCC) accounts for 20-30% of lung
cancer cases, new treatment options are limited. The CA031 study showed that nanoparticle …

Efficacy and safety of second‐line chemotherapy for patients with advanced non‐small cell lung cancer complicated by interstitial lung disease

K Otsuka, H Nokihara, A Mitsuhashi, R Ozaki… - Thoracic …, 2022 - Wiley Online Library
Background Treatment of non‐small cell lung cancer (NSCLC) patients with interstitial lung
disease (ILD) is limited because of the risk of its acute exacerbation (AE). Furthermore, the …

A phase II feasibility study of carboplatin and nab‐paclitaxel for advanced non‐small cell lung cancer patients with interstitial lung disease (YLOG0114)

H Sakashita, K Uchibori, Y Jin, T Tsutsui… - Thoracic …, 2022 - Wiley Online Library
Background A standard treatment regimen for advanced non‐small cell lung cancer
(NSCLC) patients with interstitial lung disease (ILD) has not been established since most …

Efficacy and safety of combined carboplatin, paclitaxel, and bevacizumab for patients with advanced non-squamous non-small cell lung cancer with pre-existing …

Y Enomoto, H Kenmotsu, N Watanabe… - Anticancer …, 2015 - ar.iiarjournals.org
Aim: To investigate the efficacy and safety of carboplatin, paclitaxel, and bevacizumab (CPB)
combination chemotherapy in patients with non-squamous non-small cell lung cancer …